Regeneron CEO: Anticipating PCSK9 launch, but worried about pricing debate

Regeneron ($REGN) is charging toward an FDA submission for its cholesterol-fighting drug candidate alirocumab. And in hopes of approval, it's working on launch plans with partner Sanofi ($SNY). But in the meantime, CEO Leonard Schleifer says he's worried that the brouhaha over drug prices might undermine Regeneron's pricing power. Report

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.

Bristol-Myers Squibb and Pfizer's Eliqus has taken the U.S. warfarin alternative market by storm, but can afib screening amp it up even more?